All In Biotech

Drug Trial Radar · NCT03711578

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

An Open Label, Phase II Study to Evaluate the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Adult Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Last checked: Nov 19, 2026Latest source record: Aug 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Nov 25, 2018

Primary completion

Jun 16, 2020

Study completion Oct 16, 2020

Sponsor

Lead sponsor
Rhizen Pharmaceuticals SAIndustry
Sponsor type
Industry
First posted
Oct 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the anti-tumor activity and safety of Tenalisib in patients with relapsed/refractory indolent Non-Hodgkin's Lymphoma (iNHL),

Conditions

  • Non Hodgkin Lymphoma

Interventions

  • Tenalisib,Drug

    BID, Orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: 7 months
  2. Complete Response RateTime frame: 7 months
  3. Progression Free Survival (PFS)Time frame: From date of first dose of tenalisib until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 7 months
  4. Duration of Response (DoR)Time frame: 7 months

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Florida cancer specialists & Research Institute

    Florida City, Florida

  • Florida Cancer Specialist/ South

    Fort Myers, Florida

  • Florida Cancer Specialists/North

    St. Petersburg, Florida

  • HCA Midwest Health Kansas City

    Kansas City, Missouri

  • Tennessee Oncology

    Chattanooga, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • Blacktown Hospital, Blacktown Cancer and Haematology Center

    Blacktown, New South Wales, Australia

  • Brisbane Clinic for Lymphoma, Myeloma and Leukaemia,

    Greenslopes, Queensland, Australia

  • John Flynn Private Hospital,

    Tugun, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.